Clinical Aspects of Gestational Trophoblastic Disease

Part of the Current Clinical Pathology book series (CCPATH)


Gestational trophoblastic disease (GTD) is a rare entity including hydatidiform moles, invasive moles, choriocarcinomas, placental site trophoblastic tumors (PSTTs), and epithelioid trophoblastic tumors (ETTs). All these conditions arise from the placental villous trophoblast. Choriocarcinomas, PSTT, and ETT are also referred to as gestational trophoblastic neoplasia (GTN) because they can be associated with progressive or invasive disease.


Human chorionic gonadotropin Methotrexate EMA-CO Hydatidiform mole Choriocarcinoma 


  1. 1.
    Behtash N, Behnamfar F, Hamedi B, Ramzanzadeh F. Term delivery following successful treatment of choriocarcinoma with brain metastases, a case report and review of literature. Arch Gynecol Obstet. 2009;279:579–81.PubMedGoogle Scholar
  2. 2.
    Schorge JO, Goldstein DP, Bernstein MR, Berkowitz RS. Gestational trophoblastic disease. Curr Treat Options Oncol. 2000;1:169–75.PubMedGoogle Scholar
  3. 3.
    Goto S, Ino K, Mitsui T, Kikkawa F, Suzuki T, Nomura S, et al. Survival rates of patients with choriocarcinoma treated with combination chemotherapy without hysterectomy: effects of anticancer agents on subsequent births. Gynecol Oncol. 2004;93:529–35.PubMedGoogle Scholar
  4. 4.
    Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011; 204(1):11–8.PubMedGoogle Scholar
  5. 5.
    Case AM, Wilson S, Colgan TJ, Greenblatt EM. Fertility-sparing surgery, with subsequent pregnancy, in persistent gestational trophoblastic disease. Hum Reprod. 2001;16:360–4.PubMedGoogle Scholar
  6. 6.
    Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717–29.PubMedGoogle Scholar
  7. 7.
    Palmer JR, Driscoll SG, Rosenberg L, et al. Oral contraceptive use and risk of gestational trophoblastic tumors. J Natl Cancer Inst. 1999;91:635–40.PubMedGoogle Scholar
  8. 8.
    Buckley JD, Henderson BE, Morrow CP, Hammond CB, Kohorn EI, Austin DF. Case-control study of gestational choriocarcinoma. Cancer Res. 1988;48: 1004–10.PubMedGoogle Scholar
  9. 9.
    Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours. Br J Obstet Gynaecol. 1991;98: 550–7.PubMedGoogle Scholar
  10. 10.
    Kim SJ, Bae SN, Kim JH, et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT-25 years experiences of KRI-TRD. Int J Gynaecol Obstet. 1998;60:S85–96.PubMedGoogle Scholar
  11. 11.
    Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet. 2009;374:48–55.PubMedGoogle Scholar
  12. 12.
    Horowitz NS, Goldstein DP, Berkowitz RS. Management of gestational trophoblastic neoplasia. Semin Oncol. 2009;36:181–9.PubMedGoogle Scholar
  13. 13.
    Cole LA. New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrinol. 2009;7(8):1–37.Google Scholar
  14. 14.
    Swaminathan N, Bahl OP. Dissociation and recombination of the subunits of human chorionic gonadotropin. Biochem Biophys Res Commun. 1970;40: 422–7.PubMedGoogle Scholar
  15. 15.
    Muller CY, Cole LA. The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol. 2009;112:663–72.PubMedGoogle Scholar
  16. 16.
    Cole LA, Bulter SA, Khanlian SA, et al. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol Oncol. 2006;102:151–9.PubMedGoogle Scholar
  17. 17.
    Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. Gynecol Oncol. 2010;116:3–9.PubMedGoogle Scholar
  18. 18.
    Cole LA, Khanlian SA, Muller CY, Giddings A, Kohorn E, Berkowitz R. Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free β-subunit, a reliable marker of placental site trophoblastic tumors. Gynecol Oncol. 2006;102:160–4.PubMedGoogle Scholar
  19. 19.
    Ngan HY, Chan FL, Au VW, Cheng DK, Ng TY, Wong LC. Clinical outcome of micrometastasis in the lung in stage IA persistent gestational trophoblastic disease. Gynecol Oncol. 1998;70:192–4.PubMedGoogle Scholar
  20. 20.
    Darby S, Jolley I, Pennington S, Hancock BW. Does chest CT matter in the staging of GTN? Gynecol Oncol. 2009;112:155–60.PubMedGoogle Scholar
  21. 21.
    Cole LA, Khanlian SA. The need for a quantitative urine hGC assay. Clin Biochem. 2009;42:676–83.PubMedGoogle Scholar
  22. 22.
    Thirumagal B, Sinha D, Raghavan R, Bhatti N. Gestational trophoblastic neoplasia: are we compliant with the standards? J Obstet Gynecol. 2009; 29:434–6.Google Scholar
  23. 23.
    Bracken MB. Incidence and aetiology of hydatidiform mole: an epidemiological review. Br J Obstet Gynaecol. 1987;94:1123–35.PubMedGoogle Scholar
  24. 24.
    Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med. 1994;39: 155–62.PubMedGoogle Scholar
  25. 25.
    Berkowitz RS, Cramer DW, Bernstein MR, Cassells S, Driscoll SG, Goldstein DP. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol. 1985;152:1016–20.PubMedGoogle Scholar
  26. 26.
    Parazzini F, La Vecchia C, Mangili G, et al. Dietary factors and risk of trophoblastic disease. Am J Obstet Gynecol. 1988;158:93–9.PubMedGoogle Scholar
  27. 27.
    Abike F, Temizkan O, Payasli A, Avsar F, Karahan N, Baspinar S. Postmenopausal complete hydatidiform mole: a case report. Maturitas. 2008;59:95–8.PubMedGoogle Scholar
  28. 28.
    Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales 1973–1983. Lancet. 1986; 328:673–7.Google Scholar
  29. 29.
    Garrett LA, Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med. 2008; 53:481–6.PubMedGoogle Scholar
  30. 30.
    Sebire NJ, Fisher RA, Foskett M, Rees H, Seckl MJ, Newlands ES. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 2003;110:22–6.PubMedGoogle Scholar
  31. 31.
    Ghazi GF, Donovan PO. Partial mole in ectopic pregnancy. Gynecol Surg. 2006;3:141–3.Google Scholar
  32. 32.
    Szulman A, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphological correlations. Am J Obstet Gynecol. 1978;113:665–71.Google Scholar
  33. 33.
    Lawler SD, Fisher RA, Dent J. A prospective genetic study of complete and partial hydatidiform moles. Am J Obstet Gynecol. 1991;164:1270–7.PubMedGoogle Scholar
  34. 34.
    Lipata F, Parkash V, Talmor M, Bell S, Chen S, Maric V, et al. Precise DNA genotyping diagnosis of hydatidiform mole. Obstet Gynecol. 2010;115:784–94.PubMedGoogle Scholar
  35. 35.
    Kajii T, Ohama K. Androgenetic origin of hydatidiform mole. Nature. 1977;268:633–4.PubMedGoogle Scholar
  36. 36.
    Fisher RA, Newlands ES. Gestational trophoblastic disease: molecular and genetic studies. J Reprod Med. 1998;43:81–97.Google Scholar
  37. 37.
    Czernobilsky B, Barash A, Lancet M. Partial moles: a clinicopathologic study of 25 cases. Obstet Gynecol. 1982;59:75–7.PubMedGoogle Scholar
  38. 38.
    Hou JL, Wan XR, Xiang Y, Qi QW, Yang XY. Changes of clinical features in hydatidiform mole: analysis of 113 cases. J Reprod Med. 2008;53: 629–33.PubMedGoogle Scholar
  39. 39.
    Santos-Ramos R, Forney JP, Schwartz BE. Sonographic findings and clinical correlations in molar pregnancy. Obstet Gynecol. 1980;56:186–92.PubMedGoogle Scholar
  40. 40.
    Sebire NJ, Fisher RA, Rees HC. Histopathological diagnosis of partial and complete hydatidiform mole in the first trimester of pregnancy. Pediatr Dev Pathol. 2003;6:69–77.PubMedGoogle Scholar
  41. 41.
    Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;1122:654–62.Google Scholar
  42. 42.
    Elias K, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women older than age 50. J Reprod Med. 2009;55:208–12.Google Scholar
  43. 43.
    Seckl MJ, Dhillon T, Dancey G, et al. Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy? J Reprod Med. 2004;49: 527–30.PubMedGoogle Scholar
  44. 44.
    Khoo SK, Sidhu M, Baartz D, Yip WL, Tripcony L. Persistence and malignant sequelae of gestational trophoblastic disease: clinical presentation, diagnosis, treatment and outcome. Aust N Z J Obstet Gynecol. 2010;50:81–6.Google Scholar
  45. 45.
    Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med. 2002;47: 445–50.PubMedGoogle Scholar
  46. 46.
    Behtash N, Zarchi MK. Placental site trophoblastic tumor. J Cancer Res Clin Oncol. 2008;134:1–6.PubMedGoogle Scholar
  47. 47.
    Seckl MJ, Rustin GJS, Newlands ES, Gwyther SJ, Bomanji J. Pulmonary embolism, pulmonary hypertension, and choriocarcinoma. Lancet. 1991;338:1313–5.PubMedGoogle Scholar
  48. 48.
    Newlands ES, Holden L, Seckl M, McNeish I, Strickland S, Rustin GJ. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med. 2002;47:465–71.PubMedGoogle Scholar
  49. 49.
    Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol. 2007;19:486–91.PubMedGoogle Scholar
  50. 50.
    Sebire NJ, Lindsay I. Current issues in the histopathology of gestational trophoblastic tumors. Fetal Pediatr Pathol. 2010;29:30–44.PubMedGoogle Scholar
  51. 51.
    Machtinger R, Gotlieb WH, Korach J, Fridman E, Apter S, Goldenberg M, et al. Placental site trophoblastic tumor: outcome of five cases including fertility preserving management. Gynecol Oncol. 2005; 96:56–61.PubMedGoogle Scholar
  52. 52.
    Leiserowitz GS, Webb MJ. Treatment of placental site trophoblastic tumor with hysterotomy and uterine reconstruction. Obstet Gynecol. 1996;88: 696–9.PubMedGoogle Scholar
  53. 53.
    Numnum TM, Kilgore LC, Conner MG, Strughn JM. Fertility sparing therapy in a patient with placental site trophoblastic tumor: a case report. Gynecol Oncol. 2006;103:1141–3.PubMedGoogle Scholar
  54. 54.
    Tsuji Y, Tsubamoto H, Hori M, Ogasawara T, Koyama K. Case of PSTT treated with chemotherapy followed by open uterine tumor resection to preserve fertility. Gynecol Oncol. 2002;87:303–7.PubMedGoogle Scholar
  55. 55.
    Lan C, Li Y, He J, Liu J. Placental site trophoblastic tumor: lymphatic spread and possible target markers. Gynecol Oncol. 2010;116:430–7.PubMedGoogle Scholar
  56. 56.
    Chatterjee S, Hancock BW, Suvarna SK, et al. Placental site trophoblastic tumor – a rare cause of recurrent spontaneous pneumothoraces and conjunctival metastasis. J R Coll Physicians Edinb. 2009; 39:129–33.Google Scholar
  57. 57.
    Kohorn EI. Long-term outcome of placental-site ­trophoblastic tumors. Lancet. 2009;374:6–7.PubMedGoogle Scholar
  58. 58.
    Lo C, Low I, Tan AL, Baranyai J. Epithelioid trophoblastic tumor: a case report. Int J Gynecol Cancer. 2006;16:1473–6.PubMedGoogle Scholar
  59. 59.
    Phippen NT, Lowery WJ, Leath III CA, Kost ER. Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy. Gynecol Oncol. 2010;117:387–8.PubMedGoogle Scholar
  60. 60.
    Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol. 2005;95:423–9.Google Scholar
  61. 61.
    Van Trommel NEM, Massuger LF, Verheijen RH, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005;99:6–13.PubMedGoogle Scholar
  62. 62.
    Garner EI, Feltmate CM, Goldstein DP, et al. The curative effect of a second curettage in persistant trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005;99:3–5.PubMedGoogle Scholar
  63. 63.
    Savage P, Seckl MJ. The role of repeat uterine evacuation in trophoblast disease. Gynecol Oncol. 2005;99:251–2.PubMedGoogle Scholar
  64. 64.
    Alazzam M, Tidy J, Hancock BW, et al. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2009;1: CD007102.Google Scholar
  65. 65.
    Gilani MM, Yarandi F, Eftekhar Z, et al. Comparison of pulse methotrexate and pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynecol. 2005; 45:161–4.Google Scholar
  66. 66.
    Yarandi F, Eftekhar Z, Shojaei H, et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynecol Obstet. 2008;103:33–7.Google Scholar
  67. 67.
    Osborne R, Filiaci M, Schink J, et al. A randomized phase III trial comparing weekly parenteral methotrexate and “pulsed” actinomycin as primary management for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:52.Google Scholar
  68. 68.
    Lertkhachonsuk AA, Israngura N, Wilailak S, et al. Actinomycin D versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer. 2009;19:985–8.PubMedGoogle Scholar
  69. 69.
    Wong LC, Choo YC, Ma HK. Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. Am J Obstet Gynecol. 1985;152:59–62.PubMedGoogle Scholar
  70. 70.
    Gleeson NC, Finan MA, Fiorica JV, et al. Nonmetastatic gestational trophoblastic disease: weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynecol Oncol. 1993; 14:461–5.Google Scholar
  71. 71.
    Kohorn EI. Decision making for chemotherapy administration in patients with low-risk gestational trophoblastic disease. Int J Gynecol Cancer. 1996; 6:279–85.Google Scholar
  72. 72.
    Abrao RA, de Andrade JM, Tiezzi DG, et al. Treatment for low-risk gestational trophoblastic ­disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecol Oncol. 2008;108:149–53.PubMedGoogle Scholar
  73. 73.
    Berkowitz RS, Goldstein DP, Bernstein MR. Ten year’s experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol. 1986;112:353–7.Google Scholar
  74. 74.
    McNeish IKA, Strickland S, Holden L, et al. Low risk persistent gestational trophoblastic disease: outcome following initial treatment with low-dose methotrexate and folinic acid, 1992–2000. J Clin Oncol. 2002;20:1838–44.PubMedGoogle Scholar
  75. 75.
    DuBeshter B, Berkowitz RS, Goldstein DP. Management of low-risk gestational trophoblastic tumors. J Reprod Med. 1991;36:36–9.PubMedGoogle Scholar
  76. 76.
    Soper JT, Clarke-Pearson DL, Berchuk A, et al. Five-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol. 1994;54:76–9.PubMedGoogle Scholar
  77. 77.
    Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol. 1996; 174:1917–24.PubMedGoogle Scholar
  78. 78.
    McGrath S, Short D, Harvey R. The management and outcome of women with post-hydatidiform mole “low-risk” gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU L−1. Br J Cancer. 2010;102:810–4.PubMedGoogle Scholar
  79. 79.
    Bagshawe KD. Treatment of trophoblastic tumours. Recent results. Cancer Res. 1977;62:192–9.Google Scholar
  80. 80.
    Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJS. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational ­trophoblastic tumor refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 2000;18:854–9.PubMedGoogle Scholar
  81. 81.
    Bolis G, Bonazzi C, Landoni F, et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol. 1988;31:439–44.PubMedGoogle Scholar
  82. 82.
    Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic disease: results from a cohort of 272 patients. J Clin Oncol. 1997;15:2636–43.PubMedGoogle Scholar
  83. 83.
    Matsui H, Suzuka K, Iitsuka Y, et al. Combination therapy with methotrexate, etoposide and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol. 2000;78:28–31.PubMedGoogle Scholar
  84. 84.
    Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol. 2003;91:552–7.PubMedGoogle Scholar
  85. 85.
    Lurain JR, Singh DK, Schink JC, et al. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med. 2006;51:767–72.PubMedGoogle Scholar
  86. 86.
    Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2006;16:1432–8.PubMedGoogle Scholar
  87. 87.
    Lu WG, Ye F, Shen YM, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Int J Gynecol Cancer. 2008;18:357–62.PubMedGoogle Scholar
  88. 88.
    Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol. 2006;103:479–82.PubMedGoogle Scholar
  89. 89.
    Pfeffer PE, Sebire N, Lindsay I, et al. Fertility-sparing partial hysterectomy for placental-site tumor. Lancet Oncol. 2007;8:744–6.PubMedGoogle Scholar
  90. 90.
    Lurain JR, Hoekstra AV, Schink JC. Results of ­treatment of patients with gestational trophoblastic neoplasia referred to the Brewer Tropho­blastic Disease Center after failure of treatment elsewhere (1979–2006). J Reprod Med. 2008;53: 535–40.PubMedGoogle Scholar
  91. 91.
    Baergen RB, Rutgers JL, Young RH, Osann K, Scully RE. Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol. 2006;100:511–20.PubMedGoogle Scholar
  92. 92.
    Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;96:732–7.PubMedGoogle Scholar
  93. 93.
    Newlands EY. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol. 2003;17:905–23.PubMedGoogle Scholar
  94. 94.
    Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol. 2008;19:1578–83.PubMedGoogle Scholar
  95. 95.
    Woolas RP, Bower M, Newlands ES, et al. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynecol. 1998;105:1032–5.Google Scholar
  96. 96.
    Blagden SP, Foskett MA, Fisher RA, et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer. 2002;86:26–30.PubMedGoogle Scholar
  97. 97.
    Bower M, Rustin GJS, Newlands ES, et al. Chemotherapy for gestational trophoblastic tumors hastens menopause by 3 years. Eur J Cancer. 1998;34:1204–7.PubMedGoogle Scholar
  98. 98.
    Rustin GJS, Booth M, Dent J, et al. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumors. Br Med J. 1984;288:103–6.Google Scholar
  99. 99.
    Matsui H, Iitsuka Y, Suzuka K, et al. Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor. J Reprod Med. 2004;49:531–4.PubMedGoogle Scholar
  100. 100.
    Garrett LA, Garner EI, Feltmate CM, et al. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med. 2008;53:481–6.PubMedGoogle Scholar
  101. 101.
    Rustin GJS, Newlands ES, Lutz JM, et al. Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumors (GTT) increases the incidence of second tumors. J Clin Oncol. 1996;14:2769–73.PubMedGoogle Scholar
  102. 102.
    Rojas-Espaillat L, Houck KL, Hernandez E, Berkowitz RS. Fertility-sparing surgery for persistent gestational trophoblastic neoplasia in the myometrium: a case report. J Reprod Med. 2007;52(5):431–4.PubMedGoogle Scholar
  103. 103.
    Liszka L, Wilk M, Wodolazski A, Palen P, Sikora J. Successful treatment of placental site trophoblastic tumor in twin pregnancy without hysterectomy. Tumori. 2009;95(1):108–11.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive SciencesYale University School of MedicineNew HavenUSA

Personalised recommendations